Q2 sales was again pushed by the Sigma-Aldrich acquisition (+19%) and was additionally helped by the strong organic growth in Healthcare and Life Science (+5%), coming in +18% higher at €3,805m. The gross profit margin declined from 68.5% to 65.4%. EBITDA strongly rose +27% to €1,069m, but net profit attributable to shareholders dropped by 9% to €312m. Despite higher D/A, operating CF weakened 5% to €311m due to higher NWC outflows (€-494m after €-366m). Lacking
04 Aug 2016
Good organic growth, but strong increase in NWC
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Good organic growth, but strong increase in NWC
Merck KGaA (MRCK:WBO) | 0 0 1.2% | Mkt Cap: 10,792m
- Published:
04 Aug 2016 -
Author:
Martin Schnee -
Pages:
3
Q2 sales was again pushed by the Sigma-Aldrich acquisition (+19%) and was additionally helped by the strong organic growth in Healthcare and Life Science (+5%), coming in +18% higher at €3,805m. The gross profit margin declined from 68.5% to 65.4%. EBITDA strongly rose +27% to €1,069m, but net profit attributable to shareholders dropped by 9% to €312m. Despite higher D/A, operating CF weakened 5% to €311m due to higher NWC outflows (€-494m after €-366m). Lacking